Asset profile
cizutamig
Multispecific antibody
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Asthma
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
125 competitors in this universe: 0 direct rivals (same mechanism and indication), 11 same-class, 114 same-indication; 109 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Cizutamig: this drug | Phase 1 | Multispecific antibody | BCMA x CD3 | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Teclistamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| BCD-248 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| CM336 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| Etentamig | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| F182112 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| GR1803 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| TQB2934 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| YKST02 | Phase 2 | Multispecific antibody | BCMA x CD3 | ||
| REGN5459 | Phase 1/2 | Multispecific antibody | BCMA x CD3 | ||
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Albuterol HFA (Armstrong's) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol HFA (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor |
…and 110 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
June 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (1)
May 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.